FDA — authorised 8 September 2005
- Application: NDA021692
- Marketing authorisation holder: VALEANT PHARMS
- Local brand name: ULTRAM ER
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA authorised ULTRAM ER on 8 September 2005
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 8 September 2005; FDA has authorised it.
VALEANT PHARMS holds the US marketing authorisation.